Update in Oncology
Authors: Lynn M. Schuchter
Journal: Annals of Internal Medicine (2000)

Updates from the Annual Session17 October 2000Update in OncologyLynn M. Schuchter, MD and Daniel G. Haller, MDLynn M. Schuchter, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this author and Daniel G. Haller, MDFrom University of Pennsylvania, Philadelphia, Pennsylvania.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-8-200010170-00014 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Many important papers in the field of oncology were published in 1999, but we limited our selection for this Update to studies of fairly common types of cancer. We concentrated on studies of breast cancer, cervical cancer, multiple myeloma, colorectal cancer, and prostate cancer.Breast CancerThe three articles on breast cancer presented here were among the most important articles on the topic published in 1999. The first discussed the role of prophylactic mastectomy in women who are at increased risk for breast cancer, the next examined the use of tamoxifen to prevent breast cancer, and the third evaluated the ...References1. Eisen A, Weber BL. Prophylactic mastectomy—the price of fear. N Engl J Med. 1999;340:137-8. CrossrefMedlineGoogle Scholar2. Slamon D, Leyland-Jones B, Shak S, et al . Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized multinational controlled phase III trial [Abstract]. Proc Am Soc Clin Oncol. 1998;17:98a. Google Scholar3. . Portal vein chemotherapy for colorectal cancer: a meta-analysis of 4000 patients in 10 studies. J Natl Cancer Inst. 1997;89:497-505. CrossrefMedlineGoogle Scholar4. Myers RP, Larson-Keller JJ, Bergstralh EJ, Zincke H, Oesterling JE, Lieber MM. Hormonal treatment at time of radical retropubic prostatectomy for stage D1 prostate cancer: results of long-term followup. J Urol. 1992;147:910-5. CrossrefMedlineGoogle Scholar5. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, et al . Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol. 1996;14:1756-64. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From University of Pennsylvania, Philadelphia, Pennsylvania.Corresponding Author: Lynn M. Schuchter, MD, University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104; e-mail, [email protected]med.upenn.edu.Current Author Addresses: Dr. Schuchter: University of Pennsylvania Cancer Center, 16 Penn Tower, 3400 Spruce Street, Philadelphia, PA 19104.Dr. Haller: Hospital of the University of Pennsylvania, 3400 Spruce Street, 16 Penn Tower, Philadelphia, PA 19104. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByUpdate in Women's HealthJudith M.E. Walsh, MD, MPH, Nancy C. Dolan, MD, and Pamela Charney, MD 17 October 2000Volume 133, Issue 8Page: 615-621KeywordsAdenomasAdjuvant chemotherapyBreast cancerCancer treatmentCervical cancerChemotherapyColorectal cancerProstate cancerQuality of lifeRadiation therapy ePublished: 17 October 2000 Issue Published: 17 October 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...